Prothena Corp Public (PRTA) Net Cash Flow (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Net Cash Flow of $21.9 million for Q1 2026, up 141.03% year-over-year from $9.1 million in Q1 2025, and up 194.08% quarter-over-quarter from -$23.3 million in Q4 2025.
Prothena Corp Public (PRTA) Net Cash Flow (2012 - 2026) Analysis & Trends
Prothena Corp Public's Net Cash Flow history runs 15 years deep, the most recent figure standing at $21.9 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 141.03% year-over-year to $21.9 million; the TTM figure through Mar 2026 stood at -$88.5 million (up 31.91% YoY), while the FY2025 annual figure was -$163.9 million, down 10.12% from the prior year.
- Net Cash Flow for Q1 2026 stood at $21.9 million, up from -$23.3 million in the prior quarter.
- The five-year high for Net Cash Flow was $215.6 million in Q4 2022, with the low at -$72.3 million in Q1 2024.
- The 5-year median for Net Cash Flow is -$34.2 million (2022), against an average of -$14.7 million.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow jumped 1126.65% in 2022, then plunged 480.64% in 2024.
- Prothena Corp Public's Net Cash Flow stood at $215.6 million in 2022, then sank by 124.15% to -$52.1 million in 2023, then climbed by 8.05% to -$47.9 million in 2024, then jumped by 51.31% to -$23.3 million in 2025, then surged by 194.08% to $21.9 million in 2026.
- Business Quant data shows PRTA's Net Cash Flow at $21.9 million in Q1 2026, -$23.3 million in Q4 2025, and -$40.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | -41.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.27 Mn |
| Jun 30, 2026 | -41.27 Mn |
| Mar 31, 2026 | 21.93 Mn |
| Mar 31, 2026 | 21.93 Mn |
| Dec 31, 2025 | -23.31 Mn |
| Dec 31, 2025 | -23.31 Mn |
| Sep 30, 2025 | -40.59 Mn |
| Sep 30, 2025 | -40.59 Mn |
| Jun 30, 2025 | -46.50 Mn |
| Jun 30, 2025 | -46.50 Mn |
| Mar 31, 2025 | -53.45 Mn |
| Mar 31, 2025 | -53.45 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Sep 30, 2024 | -44.86 Mn |
| Sep 30, 2024 | -44.86 Mn |
| Jun 30, 2024 | 16.26 Mn |
| Jun 30, 2024 | 16.26 Mn |
| Mar 31, 2024 | -72.32 Mn |
| Mar 31, 2024 | -72.32 Mn |